Ecallantide for the treatment of acute attacks in hereditary angioedema.

@article{Cicardi2010EcallantideFT,
  title={Ecallantide for the treatment of acute attacks in hereditary angioedema.},
  author={Marco Cicardi and Robyn J. Levy and Donald L McNeil and Huamin Henry Li and Albert L. Sheffer and Marilyn Campion and Patrick T Horn and William E Pullman},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 6},
  pages={523-31}
}
BACKGROUND Hereditary angioedema is a rare genetic disorder characterized by acute, intermittent, and potentially life-threatening attacks of edema of the skin and mucosa. We evaluated ecallantide, a newly developed recombinant plasma kallikrein inhibitor, for the treatment of acute attacks of angioedema. METHODS In this double-blind, placebo-controlled… CONTINUE READING